The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment ...
Louie Cai, MD: Manual prescreening for clinical trials is very labor intensive, taking as long as 30 minutes to an hour per ...
Microsecond green laser (520 nm; Norlase) improved visual acuity and reduced macular thickness in eyes with chronic central ...
Danon disease has been misclassified as cone dystrophy, cone-rod dystrophy, or retinitis pigmentosa; distinguishing features include the absence of optic disc pallor, bone-spicule pigmentation, and a ...
OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained ...
New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year ...
How equitably are glaucoma medications being dispensed across a universal health care system, and how have prescribing ...
Two-year PRISM results show 4D-150 gene therapy sustains wet AMD vision while cutting anti-VEGF injections up to 87%, with ...
A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, ...
Awh, MD, FASRS, presented 2-year data at ASRS 2026 showing 4D-150 gene therapy cut anti-VEGF injection burden in wet AMD, ...
As director of clinical trials, Sheth has served as principal investigator on more than 100 clinical trials, advancing ...
Presenters highlight clinical insights and lessons from recent trial data and surgical experience On efficacy, Regillo said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results